drugset

drugset / Trial / NCT05567185

A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer

NCT05567185 ↗

Phase 1 Active not recruiting 5 enrolled Janssen Pharmaceutical K.K.

Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of the study is to determine the tolerability of erdafitinib intravesical delivery system (TAR-210) in Japanese participants.

Timeline

Start: 2023-03-03
Primary completion: 2025-03-11
Completion: 2026-08-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Erdafitinib	Small molecule	—	Other

Indications